默沙东砍掉IL-2与康方单抗项目,21亿美元投入或打水漂

Ofweek光电信息网
Jul 31

7月29日,默沙东于在发布的第二季度项目进展报告中披露,公司决定终止多个重磅研发项目,以配合其正在推进的大规模成本削减计划,并重新配置资源以支持未来增长重点。其中引人关注的,其中最受关注的两项包括:通过19亿美元从Pandion Therapeutics 手中收购获得的自身免疫疾病资产—IL-2突变蛋白MK-6194(原PT001),以及与康方生物合作开发的CTLA-4抗体MK-1308在非小细胞...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10